Alliance Resources​

​Prescription Drug Tariff Webinar

​Webinar on prescription drug tariffs and their impact on pricing, supply chains, and patient access. Our expert speaker, Marta Wosinska broke down key trends, policy changes, and what they mean for manufacturers, providers, and consumers.
READ MORE+

Request for Tariff Exemption Letter to White House Administration

On behalf of our membership, EDSA has submitted a letter to leaders within the Trump Administration expressing concerns about the potential impact of tariffs. We have requested that tariffs include an exemption for most medications and their ingredients to help reduce any additional stress on existing drug shortages and unintentionally creating additional disruptions.​
​READ MORE+

​Supply chain disruption report - Baxter North Cove Plant ​​

On September 29, 2024, Baxter announced a temporary closure of its North Cove facility in Marion, N.C., due to flooding from Hurricane Helene. This report by the EDSA Rapid Response Team provides a detailed assessment of the supply disruption, including conservation strategies for clinical providers and recommendations to support affected IV fluid production, enhancing resilience in this critical situation.
​READ MORE+
​

Supply chain disruption report - Eugia Unit 3 facility

 
​On February 5 2024, Eugia Pharma announced a voluntarily pause of manufacturing operations at their Unit 3 facility in Hyderabad, India. This report by the EDSA Rapid Response Team offers an in-depth assessment of the supply disruption, including stakeholder-specific recommendations and mitigation strategies for a vulnerable group of products, aimed at bolstering resilience amidst these challenges.
READ MORE+

Supply chain disruption report - Pfizer Rocky Mount facility

EDSA's recommended actions that healthcare industry stakeholders should immediately take to help minimize supply chain disruptions of sterile injectable medications in the wake of the July 19, 2023 tornado that hit Pfizer’s Rocky Mount, North Carolina facility.
READ MORE+

Summary of the End Drug Shortages Alliance Committees

This collaborative report by EDSA's committee leaders outlines the purpose, current state, areas of focus and goals for each committee as well as the gaps, barriers, and expected actions related to their scope.
READ MORE+

White paper: Implications of the National BCG Drug Shortage

Since 2019, Bacillus Calmette-Guerin (BCG), used in the treatment of bladder cancer, has experienced a significant supply disruption due to a reduction in the number of pharmaceutical manufacturers in the market.
​READ MORE+​

Supply chain disruption report - Akorn Pharmaceuticals

In February 2023, Akorn Pharmaceuticals shut down all US operations secondary to bankruptcy. Prior to Akorn closing, their portfolio included over 100 medications. The generic manufacturer most noted for their ophthalmic products was also the sole manufacturer for numerous acute care injectables.​
READ MORE+

Drugmakers urged to boost production of bladder cancer drug (fiercepharma.com)

Amid a global drug shortage, thousands of patients with bladder cancer are unable to receive their recommended treatment each year. While Merck has pledged to make as many doses as it can, the company’s efforts aren't enough.
​READ MORE+

Thousands of people can't get full treatments of a lifesaving cancer drug (CNN)

"This is a terrible crisis. We should be doing everything we can to give every single one of these patients the best chance of survival," said Laura Bray, a board member of the End Drug Shortages Alliance, one of the sponsors of the report. "It's heartbreaking, and we must do better."
READ MORE+

Supply chain disruption report - Teva location in Irvine, California

In May 2022, Teva closed a manufacturing plant in Irvine, California. This document provides a market analysis of the affected products and is also intended to aid in understanding the current supply chain.​
READ MORE+